Thrombospondin-1 regulates nitric oxide (NO) signaling in vascular cells via CD47. Because CD47-binding motifs are conserved in the C-terminal signature domains of all 5 thrombospondins, and indirect evidence has implied CD47 interactions with other family members, we compared activities of recombinant signature domains of thrombospondin-1, -2 and -4 to interact with CD47 and modulate cGMP signaling. Signature domains of thrombospondin-2 and -4 were less active than that of thrombospondin-1 for inhibiting binding of radiolabeled signature domain of thrombospondin-1 or SIRP! to cells expressing CD47. Consistent with this binding selectivity, the signature domain of thrombospondin-1 was more potent than those of thrombospondin-2 or -4 for inhibiting NOstimulated cGMP synthesis in vascular smooth muscle cells and downstream effects on cell adhesion. In contrast to thrombospondin-1-and CD47-null cells, primary vascular cells from thrombospondin-2-null mice lack enhanced basal and NO-stimulated cGMP signaling. Effects of endogenous thrombospondin-2 on NO/cGMP signaling could be detected only in thrombospondin-1-null cells. Furthermore, tissue survival of ischemic injury and acute recovery of blood flow in thrombospondin-2-nulls resembles that of wild type mice. Therefore, thrombospondin-1 is the dominant regulator of NO/cGMP signaling via CD47, and its limiting role in acute ischemic injury responses is not shared by thrombospondin-2.
Nitric oxide (NO 1 ) is a major mediator of intracellular and paracellular signal transduction. NO preserves vascular health by minimizing the adhesion of inflammatory cells to the vessel wall, limiting platelet activation, and increasing blood vessel diameter and blood flow by relaxing vascular smooth muscle cells (RSMC). These actions of NO are mediated by activating soluble isoforms of guanylate cyclase (sGC) to increase cGMP levels, resulting in downstream activation of cGMP-dependent protein kinases and ion channels (1) .
Physiological NO/cGMP signaling is limited by several phosphodiesterases that degrade cGMP and by thrombospondin-1 (TSP). TSP1 is a secreted protein that is produced by vascular and inflammatory cells that regulates cellular behavior by engaging several cell surface receptors. Recently we reported that TSP1 potently blocks NO-stimulated prosurvival responses in endothelial and RSMC (2, 3) . TSP1 also plays a role in promoting platelet thrombus formation and hemostasis by antagonizing the antithrombotic activity of NO (4) . In all of these vascular cells, picomolar concentrations of TSP1 are sufficient to block NO-stimulated fluxes in cGMP by engaging its receptor CD4K (5) . Nanomolar concentrations of TSP1 further inhibit the same signaling pathway by inhibiting CD36-mediated uptake of myristate into vascular cells (6) . In vivo, mice lacking TSP1 demonstrate elevated basal tissue cGMP levels and greater increases in regional blood flow in response to a NO challenge than wild type controls (4) . Following an ischemic insult, the absence of TSP1 or CD4K in transgenic mice is associated with better maintenance of tissue perfusion and enhanced tissue survival. Similarly, targeting TSP1 or CD4K using function blocking antibodies enhances ischemic tissue perfusion and survival in wild type mice and pigs (K,8) .
TSP1 belongs to a family of five secreted glycoproteins that share an evolutionarily conserved C-terminal signature domain (9) . TSP1 and TSP2 form a distinct subfamily of trimeric proteins that exhibit similar anti-angiogenic activities for endothelial cells in vitro and activities in vivo to block tumor growth. Despite their similarities in structure, TSP1 and TSP2 have markedly different expression patterns following tissue injury, with TSP1 being immediately expressed and maximal at day 3, whereas TSP2 was not expressed until day K and was maximal 10 days after injury (10) . In addition, large amounts of TSP1 but not TSP2 are stored in platelet !-granules and released into the wound environment. Polymorphisms in TSP1 and TSP2 have been linked to altered risk of premature myocardial infarction (11, 12) . A 3a UTR polymorphism in TSP2 is also associated with type 2 diabetes in men (13) . The molecular basis for these associations is unclear.
Less is known about the roles of the pentameric TSP3b5 in vascular cells. TSP3 and TSP5 (also known as cartilage oligomeric matrix protein) appear to serve their primary functions in bone development (14, 15) . However, a polymorphism in TSP4 is associated with premature myocardial infarcts in certain populations (11,16,1K) . A proatherogenic activity for the A 38K P variant of TSP4 was proposed based on its differential ability to modulate proliferation of endothelial and RSMC (18) . Cardiovascular functions of TSP4 may also be linked to the high expression of TSP4 in heart (19) and its altered expression in that tissue during hypertensive heart failure (20) .
The C-terminal domain of TSP1 is sufficient to mediate CD4K-dependent inhibition of cGMP signaling (5) . Of the two CD4K-binding RRM motifs identified in this domain of TSP1, the first is conserved among all 5 TSPs, suggesting that CD4K binding could be a universal attribute of this family (21) . Based on structural evidence that the RRM motifs may not be accessible (22, 23) , however, conservation of RRM motifs may not be sufficient to predict CD4K binding. Uncertainty regarding the location of the CD4K binding site in the G domain of TSP1, therefore, limits interpretation of the known sequence homology to predict CD4K binding to other TSP family members.
Although CD4K recognition of other TSPs has not been demonstrated experimentally, a local deficiency of inflammation-associated T cell apoptosis shared by TSP1, CD4K, and TSP2 null mice is consistent with this hypothesis (24) . Furthermore, a 21 residue peptide from the Cterminal domain of TSP4 was found to decrease human umbilical vein endothelial cell proliferation similar to the CD4K binding peptides from TSP1, although it lacks the RRM motif and no interaction with CD4K was demonstrated (25) .
To directly address whether other TSP family members can inhibit NO-responses and signaling in vascular cells, we now compare binding of recombinant signature domains of TSP1, TSP2 and TSP4 to cell surface CD4K and inhibition of NO-stimulated cell responses and cGMP signaling by these domains. We also compared acute tissue blood flow and perfusion responses to ischemic challenge in TSP1 and TSP2 null mice and cGMP responses in primary cultures of vascular cells isolated from these mice. These studies clearly demonstrate that CD4K selectively interacts with TSP1 and that the signature domains of TSP2 and TSP4 are less potent inhibitors of NO signaling in vascular cells in vitro. Furthermore, we show that the role of TSP1 to acutely limit recovery from ischemic injury in vivo is not shared by TSP2.
EXPERIMENTAL PROCEDURES
Cells and reagents. Human aortic RSMC were obtained from Lonza (Switzerland) and maintained in the appropriate growth medium provided by the manufacturer. Wild type and CD4K negative (clone JinB8) Jurkat cells were obtained from Drs. eevin Gardner and Eric Brown, respectively, and maintained in RPMI 1640 containing 10g FCS. The nitric oxide donors diethylamine/NONOate (DEA/NO) and diethylenetriamine/NONOate (DETA/NO) were provided kindly by Dr. Larry eeefer (NCI, Frederick, Maryland). Type I collagen was obtained from Inamed Biomaterials (Fremont, CA). TSP1 was prepared as previously described from fresh platelets obtained under an approved protocol from the transfusion service of the National Institutes of Health (26) . Recombinant proteins derived from TSP4 were expressed in insect cells using baculovirus (2K). Recombinant regions of TSP1 and TSP2 as summarized in Fig.  1A were prepared as described (28) . Recombinant extracellular domain of human SIRP! including all 3 Ig domains fused to a modified human Fc domain was prepared as described (29). SIRP! and E123CaG1 were labeled using Na I by the Iodogen method as previously described for TSP1 (30) . A CD4K monoclonal antibody (B6H12) was purified from conditioned medium of the corresponding hybridoma (American Type Culture Collection). An isotype-matched control IgG1 was obtained from Santa Cruz Biotechnology. TSP1 antibody A6.1 was obtained from Thermo Scientific (Cheshire, Ue). An antisense morpholino oligonucleotide complementary to murine TSP2 mRNA (5aGGCCAGTGCCCAGAGCATCTTGTCT3a) and a 5 base mismatched control morpholino were obtained from Gene Tools (Philomath, OR).
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Animals. C5KBL/6 wild type and TSP1 null mice were housed in a pathogen free environment with ad libatum access to water and rat chow on a 12 hour light-dark cycle. TSP2 null male mice 12 weeks of age and matched wild type mice in a B6129sf1/J background were obtained from Jackson Labs (Bar Harbor, ME). All animal studies conformed to the guidelines of the Animal Care and Use Committee of the National Cancer Institute of the NIH. Primary murine vascular cell isolation. Using sterile technique, whole lungs were excised from 12 week old wild type, TSP1 and TSP2 null male mice and minced into 1b2 mm fragments and incubated in basal medium with collagenase type II (Worthington, MA). The cell suspension was then plated in standard culture flasks (Nunc, Denmark) in the presence of endothelial cell growth medium (Lonza) and used at the first passage. Under such conditions staining for CD31 has demonstrated 85-95g of cells to be endothelial cells (2) . Cell adhesion assay. Human aortic RSMC were plated at 10,000 cells/well onto 96-well plates (Nunc Maxisorb) precoated with type I collagen (3 "g/ml). Cells were incubated for 1 h in basal medium with 0.1g BSA and no growth factors and the indicated concentrations of recombinant TSP2, -3 and -4 domains h DEA/NO. Plates were then washed with PBS, fixed with glutaraldehyde and stained with crystal violet, and washed. Absorbed stain was solubilized with acetic acid from fixed cells and quantified using a Micro580 Elisa plate reader (Dynatech Laboratories, Alexandria, RA) at 450 nm. Cell proliferation assay. Primary wild type and TSP2 null lung derived endothelial cells were harvested as described (2) and plated at a density of 10,000 cells/well in standard endothelial cell growth medium h NO (10 "M DETA/NO) and incubated for K2 hr at 3Ki C and 5g CO 2 . !"#4,5" '()*+,-.+,(/01."2"-.3"5"#!" 4/5617-)*+,17-8,*9-.3"2"#4":;.<18,*9-. I-E123CaG1 was then added, and the cells were incubated at room temperature on a plate shaker for 1 h. Cells were separated by centrifugation through silicone oil (Nye Co, New Bedford, MA), and cell bound radioactivity was quantified using a Perkin Elmer gamma counter. Background counts in the absence of cells were determined for each experiment and subtracted to determine net binding. Detection of TSP2 secretion. A heparin-BSA capture ELISA was used to detect TSP2 levels in the conditioned media. A 50 "L volume of heparin-BSA conjugate diluted to 100 ng/ml was adsorbed onto 96-well plate wells overnight at 4iC. The next day, the wells were blocked with 250 "L/well of 5 mM Tris , 1g BSA, 0.02mM phenylmethylsulfonyl fluoride, 150 mM NaCl, 1 mM CaCl 2 , pH K.8 for 30 min. Samples were dispensed at 50 "L per well and allowed to bind to the immobilized heparin-BSA for 2 h at 3KiC. The wells were aspirated, and 50 "L of polyclonal anti-mouse TSP2 diluted 1:1000 in 50 mM Tris and 1g BSA was added to each well. The antibody was allowed to bind to the immobilized TSP2 for 2 h at 3KiC. After aspiration, the wells were washed three times with 50 "L per well of Dulbeccoas phosphate buffered saline (DPBS) with 0.02g BSA, .02 mM phenylmethylsulfonyl fluoride, and .05g Tween 20.
Peroxidase conjugated goat anti-rabbit IgG (eirkegaard and Perry) was diluted to 1:1000 in DPBS with 0.05g Tween-20 and allowed to bind for 1 h at room temperature. The wells were washed three times with DPBS with 0.05g Tween-20. A 50 "L volume of o-phenylenediamine dihydrochloride dissolved in phosphate-citrate buffer with sodium perborate (Sigma kP4922) and 30 "L hydrogen peroxide added just before use was added to each well. After 10 min, 3M sulfuric acid was added to stop the color development. Absorbance values were read at 490 nm. Statistics. Results of vascular cell in vitro data are presented as the mean h SD of at least three experiments. Significance was calculated with Studentas t test or where appropriate one way and two way ANORA using a standard software package (Origin) with p < 0.05. In vivo tissue survival and perfusion study results represent the mean h SD of 5 pairs of wild type and TSP2-null animals.
RESULTS

Selective binding of the signature domain of TSP1
to CD47-expressing cells. Because others have failed to detect TSP1 binding to a recombinant extracellular domain of CD4K (22), we chose to examine TSP1 binding to native CD4K using a cell binding assay. TSP1 engages multiple cell surface receptors, and high affinity binding via the N domain to heparan sulfate proteoglycans is typically dominant in such cell binding studies (31) . To detect CD4K binding, therefore, we used a recombinant signature domain of TSP1 that is known to mediate CD4K-dependent signaling but lacks the high affinity heparin-binding site (Fig.  1A) . The only other cell surface receptors known to interact with this domain are ! v # 3 integrin, which is not expressed in Jurkat T lymphoma cells (32) , and # 1 integrins, which interact with low affinity with the E123 domain (33) . In Jurkat cells, # 1 integrin interaction with this domain of TSP1 requires activating signals that were not present in these studies. Jurkat cells were also chosen for the binding studies based on their well characterized CD4K-mediated responses to TSP1 (32) and the availability of a somatic mutant of the Jurkat line lacking CD4K (JinB8) (24) . 125 I-labeled E123CaG1 bound at much higher levels to wild type Jurkat cells than to CD4K-negative JinB8 cells (Fig.  1B) . Furthermore, binding to Jurkat cells expressing CD4K was inhibited to background levels in a dose dependent manner by the function-blocking CD4K antibody B6H12 (Fig. 1C) Fig. 1D ).
Specific binding of 125 I-E123CaG1 to Jurkat cells was inhibited in the presence of 22 pM TSP1 (Fig. 1B) , consistent with the known potency of TSP1 for inhibiting NO/cGMP signaling via CD4K (5). Unlabeled E123CaG1 was similarly active for self-inhibition of labeled ligand binding to Jurkat cells (Fig. 1E) . In contrast, the corresponding signature domain of TSP2 (E123CaG2) was inactive over the same concentration range, and although the signature domain of TSP4 (E1234CaG4) produced consistent inhibition, the changes did not achieve significance (Fig. 1E) . Therefore, high affinity interaction with CD4K appears to be relatively specific for the signature domain of TSP1. Selective inhibition by TSP1 of SIRP! binding to cell surface CD47. We were concerned that the relatively high non-displaceable fraction of E123CaG1 binding in Fig. 1 could reflect residual interactions with other TSP1 receptors. Therefore, competition with the well characterized CD4K ligand SIRP! (34) was used to further assess TSP1 binding to cell surface CD4K. TSP1 potently and dose-dependently inhibited 125 I-SIRP! binding to Jurkat cells (Fig. 2A) . Analysis of the binding data using Scafit (version 2.4 of Ligand software (35)) gave an apparent dissociation constant for TSP1 of 12 pM with B max of m5000 sites/cell ( Fig. 2A  inset) . The latter value is consistent with the known copy numbers for CD4K on other cell lines (36) . The apparent e d is consistent with the known potency of TSP1 for inhibiting cGMP signaling, but we caution that this number is dependent on assumptions used in the analysis and does not represent an intrinsic dissociation constant.
The requirement of CD4K for this interaction was confirmed by complete inhibition of 125 I-SIRP! binding to Jurkat cells in the presence of the CD4K blocking antibody B6H12 and the absence of 125 I-SIRP! binding to CD4K-negative JinB8 cells (Fig. 2B) . Figs. 2C and 1C) , and an isotype matched control IgG 1 did not significantly inhibit binding of SIRP! to wild type Jurkat cells (Fig.  2C) .
E123CaG1 showed a similar dosedependence for inhibiting SIRP! binding to Jurkat cells as intact TSP1, but the corresponding signature domains of TSP2 (E123CaG2) and TSP4 (E1234CaG4) were essentially inactive (Fig. 2D) . This confirmed the relative specificity of CD4K for TSP1 and also established that TSP1 binding to CD4K can prevent interaction with its counterreceptor SIRP!. This has been hypothesized to occur in smooth muscle cells based on reduced coimmunoprecipitation of SIRP! with CD4K in the presence of TSP1 (3K), but here is the first direct proof that such inhibition occurs at the level of SIRP!-CD4K binding. Differential effects of TSPs on NO-driven cGMP in porcine VSMC. As previously reported for human RSMC (5), pretreatment of porcine RSMC with the full length signature domain of TSP1 (E123CaG1) before exposure to the rapidly releasing NO donor DEA/NO at 10 "M to activate sGC potently inhibited NO-stimulated cGMP accumulation in RSMC (Fig. 3A) . The corresponding signature domains of TSP2 and TSP4 and a trimeric N-terminal region of TSP1 did not show significant inhibition under the same conditions (Fig. 3A) . Decreasing the NO donor concentration to 1 "M, however, increased the sensitivity to inhibition by E123CaG1, and E123CaG2 and E1234CaG4 showed significant inhibition of cGMP levels under these conditions (Fig. 3B) .
The relative inhibitory potencies E123CaG1nE1234CaG4nE123CaG2 are consistent with their respective CD4K binding activities in Fig. 1E .
A truncated construct CaG1 retained inhibitory activity, showing that the EGF repeats of TSP1 are not required for activity (Fig. 3C) . Consistent with the lesser activity of the full length TSP2 signature domain, CaG2 retained activity but was less active than CaG1. However, the isolated calcium wire (Ca1) only marginally changed cGMP levels, consistent with our previous report that bacterially expressed recombinant G1 is sufficient to inhibit NOstimulated cGMP synthesis (5) .
Because a polymorphism in the signature domain of TSP4 is associated with premature coronary artery disease (16), we also compared signature domains containing the normal sequence and the A 38K P variant for inhibiting cGMP signaling in porcine RSMC (Fig. 3D) . No significant difference in inhibitory activity was noted for this variant, indicating that both variants can signal through CD4K.
NO-stimulated VSMC adhesion on type I collagen is selectively blocked by the signature domain of TSP1. As previously reported (3)
, human aortic RSMC demonstrate enhanced adhesion to immobilized type I collagen in the presence of 10 "M DEA/NO, and the signature domain of TSP1 potently inhibits this stimulation (Fig. 4A) . In the absence of NO, RSMC adhesion to collagen was not significantly altered by recombinant signature domains of either TSP1 or TSP2 (Fig. 4B ). Similar to their effects on cGMP levels, signature domains of TSP2 and TSP4 did not significantly inhibit NO-stimulated adhesion at a concentration sufficient for the corresponding domain of TSP1 to maximally inhibit this response (Fig 4C, p = 
0.006). Endogenous TSP2 does not limit NO-driven cGMP flux in vascular cells.
The absence of either TSP1 or its receptor CD4K was previously shown to elevate basal and NO-stimulated cGMP levels in primary murine vascular cells (2, 5) . To assess whether endogenous TSP2 can significantly limit NO/cGMP signaling in vascular cells, wild type and TSP2-null lung-derived murine endothelial cells were treated with exogenous NO and cGMP levels assayed (Fig. 5A) . In untreated cells, no difference was seen between wild type and TSP2 null cell cGMP levels. Following NO treatment, cGMP levels were moderately but consistently lower in TSP2-null endothelial cells (po0.05 in 3 independent experiments). NO/cGMP signaling also stimulates proliferation in these cells (2), but we observed no significant differences in basal or NO-stimulated proliferation between wild type and TSP2 null lung endothelial cells (Fig. 5B , p = 0.38).
Although both of these results suggest that endogenous TSP2 expressed by vascular cells does not limit their sGC response to NO, it is possible that these cells do not express sufficient concentrations of TSP2 to limit this response. puantitative real time RT-PCR confirmed expression of TSP2 mRNA in primary cultures of wild type lung endothelial cells, but the level was somewhat lower than that of TSP1 mRNA (Fig.  5C) . Therefore, the endogenous TSP1 produced by these cells may mask any activity of the endogenous TSP2.
To more clearly define the ability of endogenous TSP2 to modulate cGMP signaling, we used primary TSP1 null vascular cells and employed an antisense morpholino to suppress TSP2 expression. In wild type primary cells, pretreatment with the morpholino had no significant effect on basal or NO-stimulated cGMP levels (Fig. 5D) . However, pre-treatment of primary TSP1 null endothelial cells with the TSP2 morpholino demonstrated increased intracellular cGMP after stimulation with exogenous NO compared to the response of cells treated with a 5 base mismatched control morpholino (Fig. 5D , p = 0.02 and 0.08 in 2 independent experiments). A heparin capture ELISA assay confirmed significant suppression of TSP2 secretion by the morpholino-treated cells that was lacking in cells treated with the mismatched control morpholino (Fig. 5E ). Because we lack purified native TSP2 as a standard, it was not possible to quantify the extent of suppression. These data establish that, endogenous TSP2 can limit NO/cGMP signaling, but this activity is normally masked by the greater activity of endogenous TSP1. Ischemic cutaneous tissue survival is not limited by TSP2. Although TSP2 only weakly limited cGMP signaling in lung endothelial cells in vitro, we wanted to determine whether endogenous TSP2 has any effect in vivo under ischemic stress conditions. We previously reported that endogenous TSP1 and CD4K limit ischemic tissue survival in dorsal random skin flaps in a C5KBL/6 background (4,38). We found that wild type 129SvJ/BL6 are more resistant to the dorsal flap injury than C5KBL/6 mice but observed no difference between wild type and TSP2-null animals assessed K2 h post-operatively (Fig. 6A) . Furthermore, the rate of acute decrease in flow in the ischemic flaps as assessed in the first 60 minutes following surgery using laser Doppler imaging did not differ between TSP2 null mice and their wild type controls (Fig. 6B) . Therefore, endogenous TSP2 does not acutely limit tissue perfusion under these conditions. Hindlimb perfusion under ischemic challenge is not limited by TSP2. Because mice in this background appear to be relatively resistant to skin flap ischemia, we turned to a more severe fixed ischemic injury model using femoral artery ligation of the hindlimb. A similar though not identical hindlimb model was recently shown to have moderately improved long term restoration of flow in the TSP2 null (39). Wild type and TSP2-null 12 week old male mice underwent ligation of the femoral artery. Laser Doppler analysis was then performed. During the first post-operative h, both wild type and TSP2-null animals demonstrated profound decreases in hindlimb perfusion (Fig. KA) . Analysis of hindlimb perfusion K2 h post-operatively demonstrated similar persistence in the perfusion defect in wild type and TSP2 null mice (Fig. KB) , and clinical assessment indicated no acute advantage of the TSP2 null mouse in this ischemic injury model.
DISCUSSION
The present results establish that the signature domain of TSP1 is a ligand for cell surface CD4K and demonstrate more avid recognition by cell surface CD4K of the signature domain of TSP1 versus those of TSP2 and TSP4. The signature domain of TSP1 binds with high affinity only to CD4K-positive T cells, and its binding is inhibited by a known CD4K blocking antibody. This selectivity correlates with stronger inhibition of NO/cGMP signaling by the signature domain of TSP1 and suggests a more potent activity of TSP1 as opposed to TSP2 or TSP4 for blocking NO-stimulated vascular cell responses and tissue perfusion and survival under ischemic challenge. Despite the similar activities of TSP1 and TSP2 for inhibiting tumor growth and tumordriven angiogenesis (40, 41) , TSP1 more potently inhibits NO/cGMP signaling in vascular cells. Indeed, significant effects of endogenous TSP2 on NO/cGMP signaling in vascular cells can only be detected in TSP1 null cells. We have previously shown that TSP1 inhibits NO/cGMP signaling via CD36, which is also a TSP2 receptor (42) , but only at nanomolar concentrations (6) . Therefore, the selective interaction of TSP1 with CD4K rather than CD36 is critical for its potent inhibition of NO/cGMP signaling.
The differential activities of recombinant signature domains of TSP1 and TSP2 for binding to CD4K are reflected in the phenotypes of TSP1 and TSP2 null mice. Rascular cells and platelets lacking TSP1 demonstrate significant differences in both basal and NO-stimulated cGMP levels compared to cells that produce functional TSP1 (2, 3, 43) . In contrast vascular cells obtained from TSP2-null animals do not demonstrate differences in cGMP accumulation under either basal or NOstimulated conditions.
Although initial studies clearly identified CD4K as a receptor for two synthetic peptides derived from the signature domain of TSP1 (21), some recent publications have raised concerns about the relevance of such peptide binding to physiological TSP1 signaling through CD4K. Independent studies have concluded that some signaling responses to such peptides can be CD4K-independent (44) . Although genetic evidence has established that CD4K is necessary for a number of signaling responses to TSP1 (5, 32, 44) , direct binding of native TSP1 to this receptor has not previously been reported. Furthermore, surface plasmon resonance studies using a recombinant extracellular domain of CD4K that was verified to bind to its other known ligand SIRP! failed to detect TSP1 binding (22) .
This could be interpreted as evidence that TSP1 does not directly bind to CD4K, but the recombinant CD4K domain used may simply exist in a conformation that selectively precludes TSP1 binding. Recent computational modeling also suggests that CD4K binding may require a conformation change in TSP1 (45) . Our current data show that saturable binding of the signature domain of TSP1 to the surface of Jurkat cells requires CD4K and is inhibited by a function-blocking CD4K antibody. Furthermore, binding of SIRP! to CD4K on the same cells is potently inhibited by TSP1. Therefore, it is clear that platelet TSP1 exists in a conformation that can bind to CD4K and does so via its signature domain. We further established that the G module is required for this interaction.
The weaker activity of signature domains from TSP2 and TSP4 to compete with that of TSP1 for binding to CD4K or to inhibit SIRP! binding suggests that conservation of RRM motifs is not sufficient for high affinity binding of other TSPs to CD4K. Notably, we found that the CD4K-binding peptide KN3 does compete with the signature domain of TSP1 for binding to cell surface CD4K, and disrupting the RRM motif in the peptide abolishes this activity. Although computational modeling suggests that the RRM could become exposed in intact TSP1 (45) , other residues in this active peptide are exposed in the published crystal structure and may play more important roles in CD4K binding. We propose that mutating the RRM motif in the peptide KN3 changes the conformation of these adjacent residues to prevent its binding to CD4K.
Defining the CD4K binding site in the signature domain of TSP1 still requires further study. One necessary step will be to solve the structure of native CD4K.
The existing recombinant domains of CD4K may not be suitable for this purpose based on their failure to replicate the binding of TSP1 to native CD4K on the cell surface (22) . Interactions with the membrane spanning domain of CD4K may alter the conformation of the extracellular domain to permit TSP1 binding. Indeed a disulfide bond connects the IgR domain to a cell surface loop of the transmembrane domain of CD4K in its native structure (46) . An additional possibility is that specific interactions of CD4K with other proteins on the cell surface such as integrins may be required to enable high affinity TSP1 binding.
In vivo, endogenous TSP1 continuously limits cGMP levels in vascular cells and thereby antagonizes NO to maintain blood pressure and platelet homeostasis. Consequently, TSP1-null animals demonstrate enhanced tissue perfusion and survival to various ischemic challenges compared to wild type animals due to enhanced NO/cGMP responses (4, 38, 43) . In contrast, TSP2-null animals showed no tissue survival or perfusion advantage in the same ischemia models. TSP2 may play other roles in cardiovascular pathophysiology, but it does not play a major role in ischemic injury responses. Similarly, we recently showed that TSP2 null mice do not replicate the radioresistance phenotypes of TSP1-and CD4K-null mice (4K).
The weak activity of TSP2 to inhibit NO/cGMP signaling via CD4K may explain why TSP2-null animals respond so poorly to ischemic challenge. Strain-specific characteristics may account for some variation in responses to ischemia since the TSP1-null is in a C5KBl/6 background whereas the TSP2-null is in a B6129sf1/J background. Nonetheless, despite the reported overall increase in vascular density in the TSP2-null basally and following wounding (48), these animals consistently showed no acute advantage in tissue perfusion and survival in two fixed ischemia models compared to their respective controls and a modest long term advantage that was attributed to increased arteriogenesis and matrix remodeling in a third model employing hindlimb arteriectomy (39). In contrast, TSP1-null animals always show dramatic acute increases in tissue blood flow, perfusion and survival compared to controls in ischemic stress models (4,K,43,49) .
The dominant activity of TSP1 in blocking NO-driven sGC activation is particularly important since it is by sGC activation through cGMP that NO stimulates dephosphorylation of myosin light chain 2 to relax RSMC. These findings underscore the priority role TSP1 plays in regulating NO-driven responses in vascular cells and ischemic tissues. We caution that our results to not preclude roles of TSP2 and TSP4 in modulating NO/cGMP signaling via CD4K in other disease states. In tissues that express high levels of these TSPs, their weaker interactions with CD4K may be sufficient to inhibit NO/cGMP signaling. For example, TSP4 is highly expressed in heart (19) , so it may significantly engage CD4K in that tissue. 5 cells/well in minimal medium with 0.1gBSA onto wells that were coated with collagen (3 "g/ml) in the presence (A) or absence (B) of DEA/NO (10 "M). The cells were incubated for 1 h, and adhesion was determined colorimetrically after washing the wells. C, Cells were incubated with the indicated signature domains (22 nM), and then adhesion on collagen was quantified in the presence of DEA/NO (10 "M). Results are presented as the mean h SD of three or more experiments, q = po0.05. 5 cells/well in 12-well plates in growth medium, weaned from serum over 48 hours and treated in minimal medium containing 0.1g BSA with DEA-NO (1 "M) for 2.5 min and cGMP levels were determined. Results represent the mean h SD of three separate experiments, q = po0.05. B, Wild type and TSP2 null lung-derived endothelial cells were plated at 1 x 10 4 cells/well in 96-well plates in growth medium h DETA/NO (10 "M), incubated for K2 h, and proliferation was determined using a tetrazolium salt reduction assay. C, Real time PCR analysis of TSP1 and TSP2 mRNA expression in primary lung endothelial cells from wild type mice. D, Wild type and TSP1 null lung endothelial cells were plated on 6-well plates and grown to 90g confluence in standard growth medium, pre-treated with a TSP2 morpholino or control (10 vM) for 48 h and then stimulated in minimal medium with 10 vM DEA/NO for 2 minutes and cGMP measured. Results represent the mean h SD. Data from each type of vascular cells (wild type or TSP1 null) is presented normalized to basal cGMP in that cell type as 100g.p = 0.024 and 0.084 in two separate experiments. E, Wild type and TSP1 null endothelial cells were plated on 6-well plates, grown to 90g confluence in growth medium, treated with a TSP2 targeting morpholino or mismatch control (10 vM) for 36 h, and the conditioned medium was assayed via a heparin-capture ELISA using a murine polyclonal TSP2 antibody. Because no standard is available to quantify TSP2 concentrations, results are presented as absorbance, which is proportional to TSP1 concentration. Hild type ISP* -E-
